Carbapenemase-Producing Serratia marcescens: The Treatment Conundrum

Clinical Microbiology Newsletter

Volumn 32, Issue 10, 2010, Pages 77-78

  Bard, Jennifer Dien ^a   Hindler, Janet F ^b   Lewinski, Michael A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZTREONAM; CARBAPENEM; CARBAPENEMASE; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CANCER SURGERY; CASE REPORT; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISK DIFFUSION; DRUG WITHDRAWAL; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM STAINING; HEAD AND NECK CARCINOMA; HUMAN; MALE; POLYMERASE CHAIN REACTION; SERRATIA INFECTION; SERRATIA MARCESCENS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; THROMBOCYTOPENIA;

EID: 77952538418     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2010.04.004     Document Type: Article

References (15)

1. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. 19th informational supplement. Document M100-S19. CLSI, Wayne, PA.
2. Livermore D.M. Acquired carbapenemases. J. Antimicrob. Chemother 1997, 39:673-676.
3. Rasmussen B.A., Bush K. Carbapenem-hydrolyzing beta-lactamases. Antimicrob. Agents Chemother 1997, 41:223-232.
4. Queenan A.M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 2007, 20:440-458.
5. Naas T., et al. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob. Agents Chemother 1994, 38:1262-1270.
6. Yigit H., et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother 2001, 45:1151-1161.
7. Bradford P.A., et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 2004, 39:55-60.
8. Castanheira M., et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother 2008, 52:570-573.
9. Deshpande L.M., et al. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 2006, 56:367-372.
10. Queenan A.M., et al. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother 2000, 44:3035-3039.
11. Carrer A., et al. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada. Int. J. Antimicrob. Agents 2008, 31:181-182.
12. Poirel L., et al. SME-2-producing Serratia marcescens isolate from Switzerland. Antimicrob. Agents Chemother 2007, 51:2282-2283.
13. Gales A.C., et al. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn. Microbiol. Infect. Dis. 2001, 39:125-127.
14. Majiduddin F.K., Palzkill T. Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1. Antimicrob. Agents Chemother 2005, 49:3421-3427.
15. Queenan A.M., et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob. Agents Chemother 2006, 50:3485-3487.